卡地纳健康 CAH

DIRECTOR QUALIFICATIONS: Mr. Hollar has served as CEO of Cardinal Health since September 2022, following his tenure as CFO from May 2020 to August 2022. His deep understanding of the company's operations, strategy, and stakeholders, including its customers, suppliers, employees, and shareholders, provides the Board with unique and valuable insight into the business and industry landscape. Mr. Hollar brings extensive leadership experience in executive, financial, and operational management across five public companies, including serving as CFO at three of them. His expertise spans financial strategy, capital deployment, tax, investor relations, accounting, and financial reporting. He also has significant experience in capital markets, mergers and acquisitions, international operations, and information technology as well as corporate governance, human capital management, and regulatory compliance. During his time at Cardinal Health, Mr. Hollar has played a key role in prioritizing investments in growth areas, strengthening the company's balance sheet, and returning capital to shareholders. In addition to his role at Cardinal Health, he serves on the board of directors of DaVita Inc., where he chairs the Audit Committee, further contributing financial oversight and governance expertise to our Board. PROFESSIONAL EXPERIENCE: CEO of Cardinal Health (since 2022) CFO of Cardinal Health (2020 - 2022) Executive Vice President and CFO of Tenneco Inc., a global automotive products and services company (2018 - 2020) Senior Vice President Finance at Tenneco Inc. (2017 - 2018) CFO of Sears Holding Corporation, a holding company for large consumer retailers across the United States (2016 - 2017) (Sears filed for Chapter 11 bankruptcy in October 2018) Also served as Corporate Controller for Delphi Automotive and Vice President of Finance for the powertrain systems division, which included oversight of the Europe, Middle East, and Africa regions Earlier in his career, held finance positions of increasing responsibility in Navistar's engine group, South American operations, and corporate financial planning and analysis OTHER PUBLIC COMPANY DIRECTORSHIPS: Current: DaVita Inc. (since 2022)

Mr. Alt has served as Chief Financial Officer since February 2023. Prior to that, Mr. Alt served as Executive Vice President and Chief Financial Officer of Sysco Corporation from December 2020.

Ms. Weitzman has served as Chief Executive Officer, Pharma segment since September 2022. From July 2017 until September 2022, Ms. Weitzman served as the President of our Pharmaceutical Distribution division.

Ms. Mayer has served as Chief Legal and Compliance Officer since March 2019.

Mr. Mason has served as Chief Executive Officer, GMPD segment since August 2019.

DIRECTOR QUALIFICATIONS: Ms. Hemingway Hall has served as Chair of the Board since March 2026. She is the retired President and CEO of Health Care Service Corporation (HCSC), the largest mutual health insurer in the United States and operator of Blue Cross and Blue Shield Plans across multiple states. With a career that began in nursing, she brings to the Board deep expertise in healthcare delivery, insurance, and policy. Her leadership at HCSC brings to the Board valuable insights into healthcare payment models, regulatory frameworks, and industry transformation. Over the course of her career, she developed significant experience in healthcare reform, regulatory compliance, government relations, finance, information technology, and human capital management. Ms. Hemingway Hall also contributes perspectives from her prior service on the boards of ManpowerGroup, where she served on the Governance and Sustainability and Audit Committees, and Halliburton. PROFESSIONAL EXPERIENCE: President and CEO of HCSC (2008 - 2016) President and Chief Operating Officer of HCSC (2007 - 2008) Executive Vice President of Internal Operations of HCSC (2006 - 2007) OTHER PUBLIC COMPANY DIRECTORSHIPS: Past: ManpowerGroup, Inc. (2011 - 2025), Halliburton Company (2019 - 2022)

DIRECTOR QUALIFICATIONS: Ms. Killefer brings over 30 years of strategic leadership experience across public and private sectors, including advising healthcare and consumer-focused organizations at McKinsey and serving as CFO and COO of a U.S. government agency. She offers the Board deep expertise in healthcare strategy, public policy and government affairs, financial oversight, and corporate governance. Ms. Killefer also contributes significant public company governance experience through her current service on the boards of Certara, where she chairs the Compensation Committee and serves on the Nominating and Corporate Governance Committee, and Meta Platforms, where she chairs the Audit and Privacy Committee. Her combined experience supports her service on the Board's Human Resources and Compensation Committee and Governance and Sustainability Committee, where she contributes valuable perspectives on regulatory and policy developments, risk management, human capital management and corporate governance matters. PROFESSIONAL EXPERIENCE: Senior Partner of McKinsey & Company, Inc., a global management consulting firm (1992 - 2013) Founder and Managing Partner of McKinsey's Public Sector Practice (2007 - 2013) Held several key leadership roles at McKinsey, including serving as a member of the firm's governing board Assistant Secretary for Management, CFO, and Chief Operating Officer for the U.S. Department of Treasury (1997 - 2000) OTHER PUBLIC COMPANY DIRECTORSHIPS: Current: Certara, Inc. (since 2021), Meta Platforms, Inc. (since 2020) Past: Natura & Co Holding S.A. (2020 - 2023)

DIRECTOR QUALIFICATIONS: Ms. Edison brings to the Board extensive executive leadership experience, having served as General Counsel and in other senior functional roles at publicly traded manufacturing companies across the medical device and packaging industries. Her background provides the Board with a blend of strategic and operational experience in key areas, including healthcare, legal and regulatory compliance, enterprise risk management, information technology, corporate governance, strategic planning, and international operations. In addition to her corporate leadership roles, Ms. Edison has prior experience in private legal practice and broad-based business acumen, which enhance her ability to navigate complex commercial, legal, and regulatory environments. Ms. Edison also contributes valuable insights gained through her service on the board of directors of Union Pacific, where she chairs the Corporate Governance, Nominating, and Sustainability Committee and serves on the Compensation and Talent Committee. PROFESSIONAL EXPERIENCE: Executive Vice President and General Counsel of Amcor plc, a global packaging company (2019 - 2021) Senior Vice President, Chief Legal Officer, and Secretary of Bemis Company, Inc., a global packaging company (from 2017 until Bemis was acquired by Amcor in 2019) Vice President, General Counsel, and Secretary of Bemis (2010 - 2016) Senior Vice President and Chief Administrative Officer of Hill-Rom Holdings Inc., a global medical device company (2007 - 2010) Vice President, General Counsel, and Secretary of Hill-Rom Holdings Inc. (2004 -2007) Began career in private legal practice OTHER PUBLIC COMPANY DIRECTORSHIPS: Current: Union Pacific Corporation (since 2021)

DIRECTOR QUALIFICATIONS: Mr. Evans brings over 25 years of financial leadership experience, having served as CFO at both Scotts Miracle-Gro and Battelle. His extensive background encompasses finance and accounting, investor relations, capital markets, corporate strategy, tax, and information technology. Mr. Evans offers deep expertise in financial reporting and internal controls and has a strong understanding of capital deployment and financial operations within a publicly traded company. In addition to his executive experience, Mr. Evans served in an interim leadership role at Cardinal Health, further enhancing his industry knowledge and company-specific insights. He currently serves on the board of directors of Scotts Miracle-Gro, where he chairs the Audit Committee, bringing valuable governance and oversight perspectives from these roles. PROFESSIONAL EXPERIENCE: Interim CFO of The Scotts Miracle-Gro Company, a consumer lawn and garden products company (August 2022 - December 2022) Interim CFO of Cardinal Health (September 2019 - May 2020) Executive Vice President and CFO of Battelle Memorial Institute, a private research and development organization (2013 - 2018) Executive Vice President, Strategy and Business Development of Scotts Miracle-Gro Company (2011 - 2013) Executive Vice President and CFO of The Scotts Miracle-Gro Company (2006 - 2013) OTHER PUBLIC COMPANY DIRECTORSHIPS: Current: The Scotts Miracle-Gro Company (since 2018)

Mr. Johri brings over 25 years of financial leadership experience from his tenure at United Technologies Corporation (UTC) and Pall Corporation. He offers the Board deep expertise in global finance and accounting, investor relations, capital markets, mergers and acquisitions, tax, information technology, and international operations. His background also includes extensive experience in financial reporting and internal controls. Through his senior leadership roles at UTC, Mr. Johri developed a strong understanding of the financial management and capital deployment strategies essential to publicly traded multinational corporations. In addition, his service on the board of directors of Boeing, where he chairs the Finance Committee and serves on the Audit Committee, gives him valuable governance experience and further enhances the Board's financial oversight capabilities. PROFESSIONAL EXPERIENCE: Operating Advisor to CD&R, a global private equity manager (since 2021); Executive Vice President and CFO of UTC, a provider of high technology products and services to the building systems and aerospace industries (2015 - 2019); CFO and Chief Accounting Officer of Pall Corporation, a global supplier of filtration, separations, and purifications products (2013 - 2014); Vice President of Finance and CFO of UTC Propulsion & Aerospace Systems, which included Pratt & Whitney and UTC Aerospace Systems (2011 - 2013); Earlier in his career, led investor relations and held senior financial roles with global business units at UTC. OTHER PUBLIC COMPANY DIRECTORSHIPS: Current: The Boeing Company (since 2020).

DIRECTOR QUALIFICATIONS: Mr. Azelby brings extensive executive leadership experience in the biopharmaceutical, oncology, and specialty pharmaceutical sectors, with particular expertise in commercial execution, manufacturing operations, and regulatory environments. His background enhances the Board's perspective on industry dynamics, growth strategy, and risk oversight in highly regulated markets. Mr. Azelby also contributes significant public company board experience, offering insights into financial oversight, compensation practices, and governance matters through his service on the boards of Tango Therapeutics, where he serves as chairman of the board and on the Compensation and Nominating and Corporate Governance Committees, ADC Therapeutics, where he serves on the Audit and Compensation Committees, and Autolus Therapeutics, where he serves on the Audit and Nominating and Governance Committees. PROFESSIONAL EXPERIENCE: President and CEO of Eliem Therapeutics, Inc., a biotechnology company focused on neuronal excitability disorders (2020 - 2023) President and CEO of Alder BioPharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on prevention of chronic migraines (2018 - 2019) Executive Vice President and Chief Commercial Officer of Juno Therapeutics, Inc., a biopharmaceutical company (2015 - 2018) Held various senior roles at Amgen Inc., a multinational biopharmaceutical company (2000 - 2015) OTHER PUBLIC COMPANY DIRECTORSHIPS: Current: ADC Therapeutics SA (since 2023), Autolus Therapeutics plc (since 2024), Tango Therapeutics, Inc. (since June 2026) Past: Terns Pharmaceuticals, Inc. (February 2025 - May 2026), Chinook Therapeutics, Inc. (2023), Eliem Therapeutics, Inc. (2020 - 2023), Clovis Oncology, Inc. (2018 - 2023)

DIRECTOR QUALIFICATIONS: Mr. Ramakrishna brings over 25 years of technology leadership experience, with deep expertise in cybersecurity, enterprise software, IT infrastructure, cloud, networking, mobile platforms, artificial intelligence, and global IT operations. As CEO of SolarWinds, he led significant technology, business model, and cybersecurity transformations, and his prior leadership roles at Pulse Secure, Citrix Systems, Polycom, Motorola, and 3COM demonstrate experience in infrastructure modernization, systems integration, and operational resilience. He also contributes meaningful public company governance experience through his service on the board of Five9, Inc., where he serves as chairman of the board and as a member of the Technology and AI Committee and Nominating and Governance Committee. His combined executive and board leadership experience strengthens the Board's oversight of cybersecurity resilience, technology-enabled operations, artificial intelligence strategy and governance, digital transformation, mergers and acquisitions, enterprise risk management, human capital management, and regulatory compliance. PROFESSIONAL EXPERIENCE: President and CEO of CDK Global, an automotive retail software provider (beginning effective October 5, 2026) President and CEO of SolarWinds Corporation, a software development company (2021 - September 30, 2026) CEO of Pulse Secure, LLC, a security software company (2015 - 2020) Senior Vice President of Products and Senior Vice President and General Management of Enterprise and Service Providers of Citrix Systems, Inc., a cloud computing and virtualization technology company (2013 - 2015) Held other senior leadership roles at Motorola, Inc., Stoke, Inc., 3COM Corporation and U.S. Robotics OTHER PUBLIC COMPANY DIRECTORSHIPS: Current: Five9, Inc. (since 2025) Past: SolarWinds Corporation (2021 - April 2025 when the company went private), Enterprise 4.0 Technology Acquisition Corp. (2021 - 2023), SailPoint Technologies Holdings, Inc. (2021 - 2022)

DIRECTOR QUALIFICATIONS: Mr. Musslewhite brings over two decades of executive leadership experience across healthcare technology, data analytics, and strategic consulting. His CEO experience at Definitive Healthcare, UnitedHealth Group's OptumInsight business, and The Advisory Board Company provides the Board with perspective on healthcare innovation, data-driven strategy, product scaling, operational execution, public company governance, and regulated healthcare markets. He also contributes valuable public company board experience through his service on the board of directors of CoStar Group, where he serves as Chair of the Compensation Committee and previously served on the former Capital Allocation Committee. His combined executive and board leadership experience supports his service as Chair of the Board's Human Resources and Compensation Committee, where he provides valuable oversight of executive compensation, talent and succession planning, human capital management, and performance-driven value creation. PROFESSIONAL EXPERIENCE: CEO of Definitive Healthcare Corp., a provider of healthcare commercial intelligence (2022 - 2024) CEO of OptumInsight, Optum360, and Optum Analytics, healthcare technology divisions of UnitedHealth Group Incorporated (2017 - 2021) CEO and Chairman of the Board of The Advisory Board Company, a healthcare consulting company (2008 - 2017) Associate Principal at McKinsey & Company prior to joining The Advisory Board Company OTHER PUBLIC COMPANY DIRECTORSHIPS: Current: CoStar Group, Inc. (since 2020) Past: Definitive Healthcare Corp. (2021 - 2024)

DIRECTOR QUALIFICATIONS: Ms. Brennan brings extensive executive leadership experience from a distinguished career in senior management roles at Johnson & Johnson (J&J), with deep expertise in healthcare, regulatory compliance, manufacturing operations, product quality, strategic planning, finance, and global markets. Her prior board service, including as chair of the board of Masimo, where she also chaired the Nominating, Compliance and Corporate Governance Committee, and as director of Coupa Software, where she chaired the Nominating and Corporate Governance Committee and served on the Audit Committee, enhances the Board's oversight of healthcare operations, quality systems, global execution, corporate governance, and human capital management matters. PROFESSIONAL EXPERIENCE: Interim CEO of Masimo Corporation, a global medical technology company (September 2024 - February 2025) Global Value Creation Leader at J&J, a researcher, developer, and manufacturer in the healthcare and consumer packaged goods fields (2019 - 2020) Company Group Chair of Medical Devices at J&J in Europe, the Middle East, and Africa (EMEA) (2015 - 2018) President of Enterprise Standards & Productivity at J&J (2014 - 2015) Worldwide President of Ethicon Energy at J&J (2012 - 2014) Regional President of Ethicon Endo Surgery for EMEA, the Mediterranean, and Iberia, at J&J (2010 - 2012) Worldwide Vice President of Business Development & Strategy for Ethicon Endo Surgery at J&J (2007 - 2009) OTHER PUBLIC COMPANY DIRECTORSHIPS: Past: Masimo Corporation (2023 - June 2026), Coupa Software Incorporated (2020 - 2023)

DIRECTOR QUALIFICATIONS: Ms. Mundkur brings over 20 years of pharmaceutical industry leadership spanning legal, quality and regulatory compliance, manufacturing and commercial operations, and strategic consulting. As the former CEO of Impopharma and Barr Laboratories, she offers deep expertise in pharmaceutical market dynamics, product quality, regulatory strategy, supply continuity, operational excellence, and global markets, supporting the Board's oversight in these critical areas. Ms. Mundkur's public company board experience further enhances her contributions, including her current service on the board of MannKind, where she serves on the Audit and the Nominating and Corporate Governance Committees. Her combined operational, regulatory, and governance experience provides the Board with a well rounded perspective on complex regulatory and commercial challenges. PROFESSIONAL EXPERIENCE: CEO and non-voting Chair of the Board of Directors at Impopharma Inc., a generic pharmaceutical inhalation development company (2013 - 2017) President of CM Strategic Advisors, consulting on global pharmaceutical business strategies (2011 - 2013) President and CEO of the U.S. Division and Head of Commercial Operations for North America for Sandoz, Inc., a division of the Novartis Group and a global generic and biosimilar pharmaceutical business (2009 - 2010) CEO of Barr Laboratories, Inc., a subsidiary of Barr Pharmaceuticals, Inc. (2008) Associate Counsel at Barr Pharmaceuticals and held several positions of increasing responsibility in the company's quality and regulatory departments (1993 - 2008) OTHER PUBLIC COMPANY DIRECTORSHIPS: Current: MannKind Corporation (since 2018) Past: Lupin Limited (2019 - 2022)

Ms. Greene has served as Executive Vice President, Chief Information Officer, and Customer Support Services since August 2022. From February 2021 until August 2022, Ms. Greene served as the Senior Vice President of our former Pharmaceutical segment Information Technology.

Ms. Pitteroff has served as Chief Human Resources Officer since January 2026. Prior to her appointment as Chief Human Resources Officer, Ms. Pitteroff served as our Senior Vice President, Human Resources beginning in October 2021 and Vice President, Human Resources - Corporate Affairs, Finance, Human Resources & Strategy beginning in August 2020.

On August 10, 2022, the Board also elected Mary C. Scherer as Senior Vice President and Chief Accounting Officer, effective September 1, 2022. Ms. Scherer has served as Senior Vice President, Internal Audit of the Company since September 2017. Prior to that, she served as Vice President, Internal Audit from February 2014 to September 2017. On March 2, 2026, Mary Scherer, Senior Vice President and Chief Accounting Officer, notified Cardinal Health, Inc. that she intends to retire in February 2027. The Company will initiate a search process to identify her successor. Ms. Scherer will continue to serve as Chief Accounting Officer until her successor is identified and onboarded to ensure a smooth transition. Mary Scherer, who will continue to serve as Chief Accounting Officer through November 5, 2026.